A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes

Ronald B. Goldberg, Daniel Einhorn, Charles P. Lucas, Marc S. Rendell, Peter Damsbo, Won Chin Huang, Poul Strange, Robert G. Brodows

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

OBJECTIVE - The objective of the study was to assess the efficacy and safety of repaglinide compared with placebo in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - This was a phase II multicenter, double-blind, placebo-controlled, randomized, dose-adjustment and maintenance trial. After screening and a 2-week washout period, 99 patients were randomized to receive either repaglinide (n = 66) or placebo (n = 33). Patients underwent 6 weeks of dose adjustment followed by 12 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA(1c)), plasma glucose, insulin, and C-peptide were measured at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. RESULTS - From baseline to last visit, mean HbA(1c) decreased from 8.5 to 7.8% in patients treated with repaglinide and increased from 8.1 to 9.3% in patients receiving placebo, with a statistically significant difference of -1.7% (P <0.0001) between treatment groups at the last visit. Mean fasting plasma glucose and postprandial glucose increased in patients receiving placebo and decreased in patients treated with repaglinide, with statistically significant (P <0.01) differences between groups at the last visit. Concentrations of fasting and postprandial insulin and C-peptide were lower at the last visit compared with baseline for patients treated with placebo and higher for patients treated with repaglinide, and the differences between groups were statistically significant (P <0.05). Overall, repaglinide was well tolerated. CONCLUSIONS - This study demonstrated that repaglinide was safe and efficacious in lowering blood glucose concentrations. In addition to overall improvement in glycemic control noted with repaglinide in both sulfonylurea-treated patients and oral hypoglycemic agent-naive patients, repaglinide had a potent glucose-lowering effect in the postprandial period.

Original languageEnglish
Pages (from-to)1897-1903
Number of pages7
JournalDiabetes Care
Volume21
Issue number11
DOIs
StatePublished - 1998

Fingerprint

repaglinide
Type 2 Diabetes Mellitus
Randomized Controlled Trials
Placebos
Therapeutics
Social Adjustment
Glucose
Fasting
C-Peptide
Hypoglycemic Agents
Postprandial Period
Maintenance
Insulin

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Goldberg, R. B., Einhorn, D., Lucas, C. P., Rendell, M. S., Damsbo, P., Huang, W. C., ... Brodows, R. G. (1998). A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care, 21(11), 1897-1903. https://doi.org/10.2337/diacare.21.11.1897

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. / Goldberg, Ronald B.; Einhorn, Daniel; Lucas, Charles P.; Rendell, Marc S.; Damsbo, Peter; Huang, Won Chin; Strange, Poul; Brodows, Robert G.

In: Diabetes Care, Vol. 21, No. 11, 1998, p. 1897-1903.

Research output: Contribution to journalArticle

Goldberg, RB, Einhorn, D, Lucas, CP, Rendell, MS, Damsbo, P, Huang, WC, Strange, P & Brodows, RG 1998, 'A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes', Diabetes Care, vol. 21, no. 11, pp. 1897-1903. https://doi.org/10.2337/diacare.21.11.1897
Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care. 1998;21(11):1897-1903. https://doi.org/10.2337/diacare.21.11.1897
Goldberg, Ronald B. ; Einhorn, Daniel ; Lucas, Charles P. ; Rendell, Marc S. ; Damsbo, Peter ; Huang, Won Chin ; Strange, Poul ; Brodows, Robert G. / A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. In: Diabetes Care. 1998 ; Vol. 21, No. 11. pp. 1897-1903.
@article{2a99b4ab0c824c3cac346fe885ec90d4,
title = "A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes",
abstract = "OBJECTIVE - The objective of the study was to assess the efficacy and safety of repaglinide compared with placebo in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - This was a phase II multicenter, double-blind, placebo-controlled, randomized, dose-adjustment and maintenance trial. After screening and a 2-week washout period, 99 patients were randomized to receive either repaglinide (n = 66) or placebo (n = 33). Patients underwent 6 weeks of dose adjustment followed by 12 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA(1c)), plasma glucose, insulin, and C-peptide were measured at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. RESULTS - From baseline to last visit, mean HbA(1c) decreased from 8.5 to 7.8{\%} in patients treated with repaglinide and increased from 8.1 to 9.3{\%} in patients receiving placebo, with a statistically significant difference of -1.7{\%} (P <0.0001) between treatment groups at the last visit. Mean fasting plasma glucose and postprandial glucose increased in patients receiving placebo and decreased in patients treated with repaglinide, with statistically significant (P <0.01) differences between groups at the last visit. Concentrations of fasting and postprandial insulin and C-peptide were lower at the last visit compared with baseline for patients treated with placebo and higher for patients treated with repaglinide, and the differences between groups were statistically significant (P <0.05). Overall, repaglinide was well tolerated. CONCLUSIONS - This study demonstrated that repaglinide was safe and efficacious in lowering blood glucose concentrations. In addition to overall improvement in glycemic control noted with repaglinide in both sulfonylurea-treated patients and oral hypoglycemic agent-naive patients, repaglinide had a potent glucose-lowering effect in the postprandial period.",
author = "Goldberg, {Ronald B.} and Daniel Einhorn and Lucas, {Charles P.} and Rendell, {Marc S.} and Peter Damsbo and Huang, {Won Chin} and Poul Strange and Brodows, {Robert G.}",
year = "1998",
doi = "10.2337/diacare.21.11.1897",
language = "English",
volume = "21",
pages = "1897--1903",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes

AU - Goldberg, Ronald B.

AU - Einhorn, Daniel

AU - Lucas, Charles P.

AU - Rendell, Marc S.

AU - Damsbo, Peter

AU - Huang, Won Chin

AU - Strange, Poul

AU - Brodows, Robert G.

PY - 1998

Y1 - 1998

N2 - OBJECTIVE - The objective of the study was to assess the efficacy and safety of repaglinide compared with placebo in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - This was a phase II multicenter, double-blind, placebo-controlled, randomized, dose-adjustment and maintenance trial. After screening and a 2-week washout period, 99 patients were randomized to receive either repaglinide (n = 66) or placebo (n = 33). Patients underwent 6 weeks of dose adjustment followed by 12 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA(1c)), plasma glucose, insulin, and C-peptide were measured at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. RESULTS - From baseline to last visit, mean HbA(1c) decreased from 8.5 to 7.8% in patients treated with repaglinide and increased from 8.1 to 9.3% in patients receiving placebo, with a statistically significant difference of -1.7% (P <0.0001) between treatment groups at the last visit. Mean fasting plasma glucose and postprandial glucose increased in patients receiving placebo and decreased in patients treated with repaglinide, with statistically significant (P <0.01) differences between groups at the last visit. Concentrations of fasting and postprandial insulin and C-peptide were lower at the last visit compared with baseline for patients treated with placebo and higher for patients treated with repaglinide, and the differences between groups were statistically significant (P <0.05). Overall, repaglinide was well tolerated. CONCLUSIONS - This study demonstrated that repaglinide was safe and efficacious in lowering blood glucose concentrations. In addition to overall improvement in glycemic control noted with repaglinide in both sulfonylurea-treated patients and oral hypoglycemic agent-naive patients, repaglinide had a potent glucose-lowering effect in the postprandial period.

AB - OBJECTIVE - The objective of the study was to assess the efficacy and safety of repaglinide compared with placebo in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - This was a phase II multicenter, double-blind, placebo-controlled, randomized, dose-adjustment and maintenance trial. After screening and a 2-week washout period, 99 patients were randomized to receive either repaglinide (n = 66) or placebo (n = 33). Patients underwent 6 weeks of dose adjustment followed by 12 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA(1c)), plasma glucose, insulin, and C-peptide were measured at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. RESULTS - From baseline to last visit, mean HbA(1c) decreased from 8.5 to 7.8% in patients treated with repaglinide and increased from 8.1 to 9.3% in patients receiving placebo, with a statistically significant difference of -1.7% (P <0.0001) between treatment groups at the last visit. Mean fasting plasma glucose and postprandial glucose increased in patients receiving placebo and decreased in patients treated with repaglinide, with statistically significant (P <0.01) differences between groups at the last visit. Concentrations of fasting and postprandial insulin and C-peptide were lower at the last visit compared with baseline for patients treated with placebo and higher for patients treated with repaglinide, and the differences between groups were statistically significant (P <0.05). Overall, repaglinide was well tolerated. CONCLUSIONS - This study demonstrated that repaglinide was safe and efficacious in lowering blood glucose concentrations. In addition to overall improvement in glycemic control noted with repaglinide in both sulfonylurea-treated patients and oral hypoglycemic agent-naive patients, repaglinide had a potent glucose-lowering effect in the postprandial period.

UR - http://www.scopus.com/inward/record.url?scp=0031724919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031724919&partnerID=8YFLogxK

U2 - 10.2337/diacare.21.11.1897

DO - 10.2337/diacare.21.11.1897

M3 - Article

C2 - 9802740

AN - SCOPUS:0031724919

VL - 21

SP - 1897

EP - 1903

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -